Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

363

10.17650/1994-4098-2008-0-3-44-50

MAMMOLOGY. PHARMACOTHERAPY

МАММОЛОГИЯ. ФАРМАКОТЕРАПИЯ

Adjuvant endocrinotherapy of postmenopausal patients with breast cancer

АДЪЮВАНТНАЯ ЭНДОКРИНОТЕРАПИЯ БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ В ПОСТМЕНОПАУЗЕ

Semiglazov

V. F.

Семиглазов

В. Ф.

Russian Federation

Malodusheva

A. A.

Малодушева

А. А.

Russian Federation

Ivanov

V. G.

Иванов

В. Г.

Russian Federation

Krivorotko

P. V.

Криворотько

П. В.

Russian Federation

ФГУ НИИ онкологии им. проф. Н.Н. Петрова Росмедтехнологий, Санкт-Петербург

16082008

44501709201417092014

2008

https://ojrs.abvpress.ru/ojrs/article/view/363

Adjuvant endocrinotherapy of postmenopausal patients with breast cancer

АДЪЮВАНТНАЯ ЭНДОКРИНОТЕРАПИЯ БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ В ПОСТМЕНОПАУЗЕ

1. Crucitta E., Fornier M.N., Locopo N. et al. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (review). Int J Oncol 2002;20(6):1283—8.

Crucitta E., Fornier M.N., Locopo N. et al. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (review). Int J Oncol 2002;20(6):1283—8.

2. Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неоадъювантное и адъювантное лечение рака молочной железы. М., МИА; 2008. с. 128—44, 178— 88, 229—30.

Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неоадъювантное и адъювантное лечение рака молочной железы. М., МИА; 2008. с. 128—44, 178— 88, 229—30.

3. Семиглазов В.Ф., Семиглазов В.В. Стандарты адъювантной эндокринотерапии рака молочной железы по материалам 10-й Международной конференции в Сан- Галлене, Швейцария, 2007. Опух жен репродукт сист 2008;(1):5—11.

Семиглазов В.Ф., Семиглазов В.В. Стандарты адъювантной эндокринотерапии рака молочной железы по материалам 10-й Международной конференции в Сан- Галлене, Швейцария, 2007. Опух жен репродукт сист 2008;(1):5—11.

4. Clemett D., Lamb H.M. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000;59(6):1279—96.

Clemett D., Lamb H.M. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000;59(6):1279—96.

5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451—67.

Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451—67.

6. Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aro- matase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23(3):619—29.

Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aro- matase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23(3):619—29.

7. Berry J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 2005;27(11):1671—84.

Berry J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 2005;27(11):1671—84.

8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687—717.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687—717.

9. Nordenskjold B., Rosell J., Rutqvist L.-E. et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97(21):1609—10.

Nordenskjold B., Rosell J., Rutqvist L.-E. et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97(21):1609—10.

10.

10. Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004;(5 Suppl 1):13—77.

Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004;(5 Suppl 1):13—77.

11.

11. Buzdar A.U., Robertson J.F.R., Eiermann W. et al. An overview of the phar- macology and pharmacokinetics of the newer generation aromatase inhibitors anas- trozole, letrozole, and exemestane. Cancer 2002;95(9):2006—16.

Buzdar A.U., Robertson J.F.R., Eiermann W. et al. An overview of the phar- macology and pharmacokinetics of the newer generation aromatase inhibitors anas- trozole, letrozole, and exemestane. Cancer 2002;95(9):2006—16.

12.

12. AstraZeneca Pharmaceuticals. Arimidex (anastrozole tablets): prescribing informa- tion (US) [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ [Accessed 2006].

AstraZeneca Pharmaceuticals. Arimidex (anastrozole tablets): prescribing informa- tion (US) [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ [Accessed 2006].

13.

13. Novartis Pharmaceuticals Corporation. Femara (letrozole tablets): prescribing infor- mation (US) [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ [Accessed 2006].

Novartis Pharmaceuticals Corporation. Femara (letrozole tablets): prescribing infor- mation (US) [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ [Accessed 2006].

14.

14. Pfizer. Aromasin (exemestane tablets): prescribing information (US) [online].Available from URL: http://www.pfizer.com [Accessed 2006].

Pfizer. Aromasin (exemestane tablets): prescribing information (US) [online].Available from URL: http://www.pfizer.com [Accessed 2006].

15.

15. Coombes R.C., Hall E., Gibson L.J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post- menopausal women with primary Am J Cancer 2006;5(4) breast cancer. Intergroup Exemestane Study. N Engl J Med 2004;350(11):1081—92.

Coombes R.C., Hall E., Gibson L.J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post- menopausal women with primary Am J Cancer 2006;5(4) breast cancer. Intergroup Exemestane Study. N Engl J Med 2004;350(11):1081—92.

16.

16. Geisler J., King N., Anker G. et al. In vivo inhibitors of aromatization by exemes- tane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4(9):2089—93.

Geisler J., King N., Anker G. et al. In vivo inhibitors of aromatization by exemes- tane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4(9):2089—93.

17.

17. Johannessen D.C., Engan T., Di Salle E. et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in post- menopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3(7):1101—8.

Johannessen D.C., Engan T., Di Salle E. et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in post- menopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3(7):1101—8.

18.

18. Coombes R.C., Hall E., Snowdon C.F. et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease- free after two to three years of tamoxifen - updated survival analysis [abstr 3]. Breast Cancer Res Treat 2004;(88 Suppl 1):7. Plus oral presentation at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11, San Antonio (TX).

Coombes R.C., Hall E., Snowdon C.F. et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease- free after two to three years of tamoxifen - updated survival analysis [abstr 3]. Breast Cancer Res Treat 2004;(88 Suppl 1):7. Plus oral presentation at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11, San Antonio (TX).

19.

19. Coombes R.C., Paridaens R., Jassem J. et al. First mature analysis of the Intergroup Exemestane Study [abstr LBA527]. J Clin Oncol 2006;24(18):933. Plus oral presenta- tion at the 42nd Annual Meeting of the

Coombes R.C., Paridaens R., Jassem J. et al. First mature analysis of the Intergroup Exemestane Study [abstr LBA527]. J Clin Oncol 2006;24(18):933. Plus oral presenta- tion at the 42nd Annual Meeting of the

20.

ASCO 2006 Jun 2-6; Atlanta (GA).

21.

20. Kudchadkar R., O'Regan R.M. Aromatase inhibitors as adjuvant therapy for post- menopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145—63.

Kudchadkar R., O'Regan R.M. Aromatase inhibitors as adjuvant therapy for post- menopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145—63.

22.

21. Younis T., Rayson D., Dewar R. et al. Modeling for cost-effective strategies in adju- vant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors [abstr 5089]. Breast Cancer Res Treat 2005;(94 Suppl 1):237—8. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8—11, San Antonio (TX).

Younis T., Rayson D., Dewar R. et al. Modeling for cost-effective strategies in adju- vant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors [abstr 5089]. Breast Cancer Res Treat 2005;(94 Suppl 1):237—8. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8—11, San Antonio (TX).

23.

22. Coleman R.E., Banks L.M., Girgis S.I. et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone bio- marker data [abstr 5076 plus poster]. 28th Annual San Antonio Breast Cancer Symposium, 2005 Dec 8-11, San Antonio (TX).

Coleman R.E., Banks L.M., Girgis S.I. et al. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone bio- marker data [abstr 5076 plus poster]. 28th Annual San Antonio Breast Cancer Symposium, 2005 Dec 8-11, San Antonio (TX).

24.

23. Lonning P.E., Geisler J., Krag L.E. et al. Effects of exemestane administered for 2 years versus placebo on bone mineral densi- ty, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126—37.

Lonning P.E., Geisler J., Krag L.E. et al. Effects of exemestane administered for 2 years versus placebo on bone mineral densi- ty, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126—37.

25.

24. Lonning P.E. Comparing cost/utility of giving an aromatase inhibitor as monother apy for 5 years versus sequential administra- tion following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17(2):217—25.

Lonning P.E. Comparing cost/utility of giving an aromatase inhibitor as monother apy for 5 years versus sequential administra- tion following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17(2):217—25.

26.

25. Lonning P.E. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res 2005;11(2 Pt 2):918—24.

Lonning P.E. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res 2005;11(2 Pt 2):918—24.

27.

26. Markopoulos C., Chrissochou M., Michailidou A. et al. Effect of exemestane on the lipidemic profile of postmenopausal operable breast cancer patients following 5- 7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005;16(8):879—83.

Markopoulos C., Chrissochou M., Michailidou A. et al. Effect of exemestane on the lipidemic profile of postmenopausal operable breast cancer patients following 5- 7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005;16(8):879—83.

28.

27. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002;288(16):2015—22.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002;288(16):2015—22.

29.

28. Fallowfield L.J., Bliss J.M., Porter L.S. et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in post- menopausal women with primary breast cancer. J Clin Oncol 2006;24(6):910—7.

Fallowfield L.J., Bliss J.M., Porter L.S. et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in post- menopausal women with primary breast cancer. J Clin Oncol 2006;24(6):910—7.

30.

29. Gil J.M., Lluch A., Gonzalez P. et al. Pharmacoeconomic analysis of exemestane versus tamoxifen as adjuvant therapy for patients with early-stage estrogen receptor- positive breast cancer [abstr PCN15]. Value Health 2005 Nov-Dec;8(6):37—8. Plus poster presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6—8, Florence.

Gil J.M., Lluch A., Gonzalez P. et al. Pharmacoeconomic analysis of exemestane versus tamoxifen as adjuvant therapy for patients with early-stage estrogen receptor- positive breast cancer [abstr PCN15]. Value Health 2005 Nov-Dec;8(6):37—8. Plus poster presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6—8, Florence.

31.

30. Anker G.B., Refsum H., Ueland P.M. et al. Influence of aromatase inhibitors on plasma total homocysteine in post- menopausal breast cancer patients. Clin Chem 1999;45(2):252—6.

Anker G.B., Refsum H., Ueland P.M. et al. Influence of aromatase inhibitors on plasma total homocysteine in post- menopausal breast cancer patients. Clin Chem 1999;45(2):252—6.

32.

31. Bundred N.J. The effects of aromatase inhibitors on lipids and thrombosis. Br Cancer 2005;(93 Suppl 1):23—7.

Bundred N.J. The effects of aromatase inhibitors on lipids and thrombosis. Br Cancer 2005;(93 Suppl 1):23—7.

33.

32. Gradishar W.J. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69(1):1—9.

Gradishar W.J. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69(1):1—9.

34.

33. Skedgel C., Rayson D., Dewar R. et al. Cost-utility evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: tamoxifen vs. anastrazole vs. tamox- ifen then exemestane [abstr 5036]. Breast Cancer Res Treat 2005;(94 Suppl 1):217—8.

Skedgel C., Rayson D., Dewar R. et al. Cost-utility evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: tamoxifen vs. anastrazole vs. tamox- ifen then exemestane [abstr 5036]. Breast Cancer Res Treat 2005;(94 Suppl 1):217—8.

35.

34. Risebrough N.A., Verma S., Trudeau M. et al. Economic evaluation of switching to exemestane at 2,5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer; a Canadian perspective [abstr 2050]. Breast Cancer Res Treat 2005;(94 Suppl 1):101. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8—11, San Antonio (TX).

Risebrough N.A., Verma S., Trudeau M. et al. Economic evaluation of switching to exemestane at 2,5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer; a Canadian perspective [abstr 2050]. Breast Cancer Res Treat 2005;(94 Suppl 1):101. Plus poster presented at the 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8—11, San Antonio (TX).